{"prompt": "['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', 'PROTOCOL AMENDMENT #_3_', 'LCCC 1726: Randomized Placebo Controlled Trial of High Dose Intravenous', 'Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell', 'Transplantation', 'AMENDMENT INCORPORATES (check all that apply):', 'X Editorial, administrative changes', 'X', 'Scientific changes (IRB approval)', 'Therapy changes (IRB approval)', 'Eligibility Changes (IRB approval)', 'AMENDMENT RATIONALE AND SUMMARY:', 'Editorial, administrative changes', '(1) The version date was updated throughout the protocol', 'Scientific changes', '(1) Throughout the protocol, we have modified the delirium assessment schedule', 'to acknowledge that there are certain situations, due to an acute medical', 'concern (e.g. intubation, sedation, etc.), in which patients are not evaluable for', 'the purposes of this study and the DRS will not be performed.', '(2) In Section 7.11 Assessment of Efficacy we have added the phrase \"in', 'evaluable patients\" to account for acute medical concerns that prevent', 'participants from being evaluated, as described above.', '(3) Throughout the protocol, we have modified the delirium assessment schedule', 'to specify that when patients develop delirium, delirium assessments will be', 'performed daily \"when scheduling permits\". This allows for greater', 'flexibility for this non-primary outcome (duration of delirium).', 'THE ATTACHED VERSION DATED 1/10/18INCORPORATES THE ABOVE', 'REVISIONS', 'ATTACH TO THE FRONT OF EVERY COPY OF PROTOCOL']['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', 'PROTOCOL AMENDMENT', 'LCCC 1726: Randomized Placebo Controlled Trial of High Dose Intravenous', 'Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell', 'Transplantation', 'AMENDMENT INCORPORATES (check all that apply):', 'X', 'Editorial, administrative changes', 'X', 'Scientific changes (IRB approval)', 'X', 'Therapy changes (IRB approval)', 'Eligibility Changes (IRB approval)', 'AMENDMENT RATIONALE AND SUMMARY:', 'Editorial, administrative changes', '(1) The version date was updated throughout the protocol', 'Scientific changes', '(1) Throughout the protocol, modified schedule of thiamine levels from days 1,', '8, 15, 22, and 29 post-transplant to allow for levels to be drawn up to one day', 'earlier or later of this specified schedule. This allows capture of thiamine', 'levels currently missed in patients who are discharged the day before their', 'anticipated next thiamine level lab draw.', 'Therapy changes', '(2) Throughout the protocol, the preparation of our intervention was changed', 'from Thiamine 200 mg diluted in 100 mL 0.9% normal saline to Thiamine', '200 mg diluted in 25 mL 0.9% normal saline. Our placebo was changed from', '100 mL 0.9% normal saline to 25 mL 0.9% normal saline to maintain', 'blinding. The intervention will be administered over 30 minutes. No changes', 'were made to strength, route (intravenous), frequency (TID), or duration', '(seven days). This modification was made in response to a severe national', 'shortage of 100 mL bags related to the hurricane in Puerto Rico. This', 'modification in no way increases risk to subjects.', 'THE ATTACHED VERSION DATED 11/16/17INCORPORATES THE ABOVE', 'REVISIONS', 'ATTACH TO THE FRONT OF EVERY COPY OF PROTOCOL']['LINEBERGER COMPREHENSIVE CANCER CENTER', 'CLINICAL ONCOLOGY RESEARCH PROGRAM', 'April 2017', 'UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL', 'PROTOCOL AMENDMENT #_1_', 'LCCC 1726: Randomized Placebo Controlled Trial of High Dose Intravenous', 'Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell', 'Transplantation', 'AMENDMENT INCORPORATES (check all that apply):', 'X', 'Editorial, administrative changes', 'X', 'Scientific changes (IRB approval)', 'X', 'Therapy changes (IRB approval)', 'Eligibility Changes (IRB approval)', 'AMENDMENT RATIONALE AND SUMMARY:', 'Editorial, administrative changes', '(1) The version date was updated throughout the protocol', '(2) Stephanie Chien added as the study coordinator', '(3) Section 7.9. Samples will be drawn by nurses rather than phlebotomists and', 'stored in McLendon laboratory. This modification in no way increases risk to', 'subjects, but only reflects the actual workflow on the Bone Marrow', 'Transplant Unit.', 'Scientific changes', '(1) Throughout the protocol, Medical/Surgical Tracking Form is omitted, as it', \"was overly inclusive and not necessary to accomplish the study's aims. In its\", 'place, a Delirium Risk Factor Form has been added, which will document', 'previous history of delirium, alcohol and substance use, and neurological', 'conditions (stroke, traumatic brain injury, seizures, abnormal brain imaging', 'findings) from chart abstraction.', '(2) Throughout the protocol, revised baseline labs to no longer include folate and', \"vitamin B12. These are also not necessary to accomplish the study's aims and\", 'not typically drawn on patients undergoing hematopoietic stem cell', 'transplantation (HSCT).', '(3) Throughout the protocol, revised schedule of baseline labs (CBC, CMP, Mg,', 'Phos) to within 2 days of transplant, rather than specifically on post-transplant', 'day 1. These labs are routinely drawn on Mondays and Thursdays, so this', 'modification prevents additional blood draws, thereby improving nursing', 'workflow and minimizing patient burden.', '(4) Class of concurrent CNS active medications will continue to be documented,', 'but throughout the protocol revised to indicate that details regarding dose,', 'route, frequency, and indication will no longer be captured, as this data will', \"not be necessary to accomplish the study's aims.\"]\n\n###\n\n", "completion": "END"}